Multiple NICUs showed improved growth & lung health in premature infants by fortifying feeds safely in the first days of life with Prolacta’s 100% human milk-based fortifiers
Type: Press Releases
Topic(s): Bronchopulmonary Dysplasia (BPD) Early Fortification Feeding Protocols Growth Necrotizing Entercolitis (NEC) Product
The preemie parent’s survival guide to the NICU now reflects the latest clinical advancements to better support parents worldwide
Type: Press Releases
Topic(s): Company Growth Parents
Preterm infants fed Prolacta’s 100% human milk-based fortifiers achieved catch-up growth by age 2 with appropriate neurodevelopmental outcomes, study says
Type: Press Releases
Topic(s): Growth Long-Term outcomes
Head-to-head subgroup analysis of human milk–based fortifiers finds significant improvements in health and brain growth measure for preemies fed mother’s milk plus Prolacta’s fortifiers
Type: Press Releases
Topic(s): Growth Neurodevelopmental Outcomes Total Parenteral Nutrition (TPN) Use
Prolacta Bioscience reassures hospitals of the safety of its human milk-based nutritional products during the coronavirus pandemic
Type: Press Releases
Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Pasteurization Quality & Safety
Microbiome and gut-brain axis in premature infants focus of 2020 International Conference on Human Milk Science and Innovation
Type: Press Releases
Topic(s): Conferences and Events Microbiome
Despite worsening prematurity birth rate, odds of survival improving with NICU adoption of Prolacta's 100% human milk-based fortifiers
Type: Press Releases
Topic(s): Growth Mortality Neurodevelopmental Outcomes
Study Reveals an Exclusive Human Milk Diet With Prolact+ H2MF, Prolacta’s 100% Breastmilk-Based Fortifier, Substantially Reduces Costs Due to Complications in the NICU
Type: Press Releases
Topic(s): Cost Savings / Cost Effectiveness
Prolacta Bioscience Launches Women’s Leadership Development Academy
Type: Press Releases
Topic(s): Company